CO-CURE: U of Utah Recruiting Fibromyalgia & FM/CFS Patients for Pregabalin Biomarker Study

[Guest guest]

Date:    Sat, 14 Jul 2012 15:57:02 -0500

From:    kelly & lt;kellylatta66@... & gt;

Subject: NOT, ACT: U of Utah Recruiting Fibromyalgia & FM/CFS Patients for

Pregabalin Biomarker Study

U of Utah Recruiting Fibromyalgia & FM/CFS Patients for Pregabalin Biomarker

Study

Why does Lyrica® (generic name pregabalin) help some FM patients and not

others?

The Department of Anesthesiology at the University of Utah, Salt Lake City,

announced July 10 that it is seeking participants for a study to investigate

Lyrica’s “effects on blood biomarkers†in patients with fibromyalgia or FM

& chronic fatigue syndrome (ME/CFS).

Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA

approval in 2007* for treatment of fibromyalgia.

Study Details

According to the July 10 blood biomarkers study announcement:

-- Researchers hope to learn more about why Lyrica is effective for some

patients and not for others.

-- Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who

are not currently using Lyrica are needed to participate in this IRB-approved

trial.

-- Eligible volunteers will receive Lyrica for five weeks and a placebo for five

weeks, and will be compensated for their time.

-- For more information, contact White (andrea.white@...)

___

* As Pfizer's Lyrica patents begin expiring, in October 2013, the $3.4 billion

annual Lyrica market will be opening to ‘generic’ (generally lower price)

versions of the drug, and as of July 5, the FDA approved marketing of a generic

pregabalin product by Lupin Pharmaceuticals.

---------------------------------------------

Send posts to CO-CURE@...

Unsubscribe at http://www.co-cure.org/unsub.htm

Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html

---------------------------------------------

Co-Cure's purpose is to provide information from across the spectrum of opinion

concerning medical, research and political aspects of ME/CFS and/or FMS.

We take no position on the validity of any specific scientific or political

opinion expressed in Co-Cure posts, and we urge readers to research the various

opinions available before assuming any one interpretation is definitive.

The Co-Cure website & lt;www.co-cure.org & gt; has a link to our complete archive

of posts as well as articles of central importance to the issues of our

community.

---------------------------------------------

[Guest guest]

The contact email address did not come out for White

(andrea.white@...)

andrea (dot) white (at) hsc (dot) utah (dot) edu

blessings

Shan

>

>

>

> Date:    Sat, 14 Jul 2012 15:57:02 -0500

> From:    kelly kellylatta66@...

> Subject: NOT, ACT: U of Utah Recruiting Fibromyalgia & FM/CFS Patients for

Pregabalin Biomarker Study

>

> U of Utah Recruiting Fibromyalgia & FM/CFS Patients for Pregabalin Biomarker

Study

>

>

> Why does Lyrica® (generic name pregabalin) help some FM patients and not

others?

>

>

> The Department of Anesthesiology at the University of Utah, Salt Lake City,

announced July 10 that it is seeking participants for a study to investigate

Lyrica’s “effects on blood biomarkers†in patients with fibromyalgia or FM

& chronic fatigue syndrome (ME/CFS).

>

> Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA

approval in 2007* for treatment of fibromyalgia.

>

>

> Study Details

>

>

> According to the July 10 blood biomarkers study announcement:

>

> -- Researchers hope to learn more about why Lyrica is effective for some

patients and not for others.

>

> -- Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who

are not currently using Lyrica are needed to participate in this IRB-approved

trial.

>

> -- Eligible volunteers will receive Lyrica for five weeks and a placebo for

five weeks, and will be compensated for their time.

>

> -- For more information, contact White (andrea.white@...)

>

> ___

>

> * As Pfizer's Lyrica patents begin expiring, in October 2013, the $3.4 billion

annual Lyrica market will be opening to ‘generic’ (generally lower price)

versions of the drug, and as of July 5, the FDA approved marketing of a generic

pregabalin product by Lupin Pharmaceuticals.

>

> ---------------------------------------------

> Send posts to CO-CURE@...

> Unsubscribe at http://www.co-cure.org/unsub.htm

> Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html

> ---------------------------------------------

> Co-Cure's purpose is to provide information from across the spectrum of

opinion concerning medical, research and political aspects of ME/CFS and/or FMS.

> We take no position on the validity of any specific scientific or political

opinion expressed in Co-Cure posts, and we urge readers to research the various

opinions available before assuming any one interpretation is definitive.

> The Co-Cure website & lt;www.co-cure.org & gt; has a link to our complete archive

of posts as well as articles of central importance to the issues of our

community.

> ---------------------------------------------

>

>

>

>